依达拉奉联合前列地尔治疗急性脑梗死43例疗效观察

摘要

目的:探讨依达拉奉联合前列地尔注射液治疗急性脑梗死的临床疗效.方法:将符合标准的80例急性脑梗死患者随机分成观察组(43例)和对照组(37例),对照组在常规治疗基础上给予丹参注射液及胞二磷胆碱注射液,观察组在常规治疗基础上给予依达拉奉和前列地尔注射液联合治疗.两组疗程均为14d,观察两组患者的神经功能缺损评分、日常活动能力评分、疗效与并发症.结果:两组患者神经功能缺损和日常活动能力评分均较治疗前明显改善(P<0.05),观察组相对于对照组更能改善神经功能缺损及提高生活能力(P＜0.05);观察组临床总有效率明显高于对照组,而并发症发生率明显低于对照组(P＜0.05).结论:依达拉奉联合前列地尔注射液治疗急性脑梗死疗效肯定,值得临床推广.%Objective: To explore the clinical efficacy of edaravone and alprostadil injection in treatment of patients with acute cerebral infarction ( ACI ). Method: 80 patients with the disease were randomly divided into observation group ( 43 cases ) and control group ( 37 cases ), patients in control group were treated with salvia miltiorrhiza injection and injection, while others were treared with edaravone and alprostadil injection. The treatment lasted for 14 days. Neurological deficit score ( NDS ), activities of daily living ability score ( ADL ) efficacy and complications were observed in all patients. Result: NDS and ADL improved significantly compared with before treatment in both groups ( P<0. 05 ). . The total effective rate of the observation group was significantly higher than that of the control group, while the complication rate of the observation group was significantly lower than that of the control group( P<0. 05 ). Conclusion: The treatment of a-cute cerebral infarction with edaravone and alprostadil injection has a satisfy curative effect, and it is worth for clinical application.